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Background
Fluoropyrimidine-based chemotherapy is the most com-
mon treatment for colon cancer, especially the combina-
tion of 5-fluorouracil (5FU) and folinic acid (FA). Despite
the existence of other treatment choices, more than 50%
of the patients in Mexico cannot afford their cost, and the
regimen used is still 5FU/FA. However, not every patient
responds to this treatment, and it will be useful to have a
biological marker that helps to predict the response to
5FU/FA giving the basis for treatment selection. The
enzyme called Methylentetrahydrofolate Reductase
(MTHFR) plays an important role in the metabolism of
folates. The MTHFR substrate is needed for the synthesis
of a tertiary complex with 5FU and thymidylate synthase,
which inhibits thymine synthesis. A mutation in MTHFR
has been identified as one of the most common polymor-
phisms in the Mexican population (thymine instead of
cytosine in gene position 677). This genetic variation has
been correlated with a reduction in the enzymatic activity
and increases substrate levels, which increases the activity
of 5FU. The aim of this study was to evaluate the presence
of C667T MTHFR polymorphism and its relation with
progression-free survival in patients with metastatic colon
cancer treated with 5FU and FA.
Materials and methods
We studied 29 patients with metastatic colon cancer
treated with 5FU/AF at the Instituto Nacional de Can-
cerología, in Mexico City. Healthy mucosa from paraffin
blocks were used to obtain DNA and determine C667T
polymorphism by PCR and allele specific digestion.
Results
The following proportions were found: 27% CC
homozygous, 52% CT heterozygous and 21% TT
homozygous. There was no difference regarding gender,
functional status, tumor differentiation, site and number
of metastases between the three groups. The median time
for progression was: CC 3.43, CT 4.77 and TT 4.80
months, respectively (p = 0.047 log rank). When compar-
ing the non-polymorphic (CC) and polymorphic groups
(CT and TT), we observed a greater time to progression
(4.80 vs. 3.43 months) in the polymorphic group (p =
0.031 log rank).
Conclusion
Our findings are the first to suggest that the C677T
MTHFR polymorphism plays a role as a predictive marker
of progression-free survival in patients with metastatic
colon cancer treated with 5FU/FA.
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